Cytokinetics, Incorporated (CYTK)
-NasdaqCM 1.82 
0.07(3.70%) 3:59PM EDT|After Hours
:
1.82 0.00 (0.00%) 4:00PM EDT - Nasdaq Real Time Price
| Prev Close: | 1.89 |
|---|
| Open: | 2.00 |
|---|
| Bid: | 1.83 x 200 |
|---|
| Ask: | 1.88 x 5000 |
|---|
| 1y Target Est: | 3.90 |
|---|
| Beta: | 1.73 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 1.81 - 2.03 |
|---|
| 52wk Range: | 0.57 - 2.03 |
|---|
| Volume: | 11,237,295 |
|---|
| Avg Vol (3m): | 1,632,530 |
|---|
| Market Cap: | 270.48M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.35 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Amgen In Focusat Seeking Alpha(Wed 9:13AM EDT)
- On The Fly: After Hours Moversat theflyonthewall.com(Tue, Jun 18)
- Hudson City Bancorp Jumps On M&T Settlement and 2 More Heavily Traded Stocks to Followat Wall St. Cheat Sheet(Tue, Jun 18)
- Cytokinetics Announces Results From ATOMIC-AHF Will Be Presented At Late Breaking Clinical Trials Session At The European Society Of Cardiology Congress 2013Thomson Reuters ONE(Tue, Jun 18)
- CYTOKINETICS INC Files SEC form 8-K, Other EventsEDGAR Online(Tue, Jun 18)
- Cytokinetics Set to Join Russell Global IndexThomson Reuters ONE(Mon, Jun 17)
- 3 Stocks Near 52-Week Highs Worth Sellingat Motley Fool(Thu, Jun 13)
- Why The Amgen And Cytokinetics Agreement Is Good Newsat Seeking Alpha(Thu, Jun 13)
- Cytokinetics Receives A Vote Of Confidence From Amgenat Seeking Alpha(Thu, Jun 13)
- Cytokinetics and Amgen expand collaborationAP(Wed, Jun 12)
- Amgen and Cytokinetics Announce Expansion of License for Omecamtiv MecarbilThomson Reuters ONE(Wed, Jun 12)
- CYTOKINETICS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity SecuritiEDGAR Online(Wed, Jun 12)
- Cytokinetics Announces Publications Relating to Fast Skeletal Troponin Activation in Nemaline MyopathyThomson Reuters ONE(Tue, Jun 4)
- CYTOKINETICS INC Files SEC form 8-K, Other EventsEDGAR Online(Tue, Jun 4)
- 4 Biotech Stocks Offering Potential, Pipeline And Priceat Seeking Alpha(Wed, May 29)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 42.82 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.37 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.10 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | -0.25 |
|---|
Business Summary
Cytokinetics, Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions.
View More